Apyx Medical Corporation
5115 Ulmerton Road
Clearwater
FL
33760
United States
Tel: 1-800-537-2790
Website: http://www.apyxmedical.com/
231 articles about Apyx Medical Corporation
-
Apyx Medical Corporation to Restate Previously Issued Financial Statements
3/16/2020
Apyx Medical Corporation announced it will be restating its previously issued consolidated financial statements for the twelve months ended December, 31 2018 and the quarterly statements for the three and nine months ended September 30, 2018 and three months ended March 31, 2019.
-
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 16, 2020
2/5/2020
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2019 will be released after the market closes on Monday, March 16.
-
Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results
1/13/2020
Apyx Medical Corporation reported preliminary revenue results for the full year and fourth quarter ended December 31, 2019.
-
Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion® Technology in Dermal Resurfacing Procedures
12/3/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and as J-Plasma® in the hospital surgical market, announced today that it has initiated subject enrollment in a U.S. Investigational Device Exemption (IDE) clinical study evaluating the use of its Renuvion technology in dermal resurfacing procedures.
-
Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook
11/11/2019
Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, reported financial results for its third quarter ended September 30, 2019.
-
CORRECTING and REPLACING Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook
11/11/2019
In the "2019 Financial Outlook" section, the fifth bulleted item should read: GAAP net loss in the range of $20.3 million to $19.8 million.
-
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November and December
11/4/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and as J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences
-
Apyx Medical Corporation Announces Subject Enrollment Initiated in Study Evaluating the Use of Renuvion® Technology in Skin Laxity Procedures in the Neck and Submental Region
10/14/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion®
-
Apyx Medical Corporation Receives 510(k) Clearance for the Apyx Plasma/RF Handpiece
10/14/2019
Apyx Medical Corporation announced that it received U.S. Food and Drug Administration 510 clearance to market and sell the Apyx Plasma/RF Handpiece, a new addition to the Renuvion product family.
-
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2019 Financial Results on November 11, 2019
9/24/2019
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), today announced that financial results for the third quarter of fiscal year 2019 will be released after the market closes on Monday, November 11.
-
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in September and October
8/22/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences:
-
Apyx Medical Corporation Reports Second Quarter and First Half of 2019 Financial Results and Updates Fiscal Year 2019 Outlook
8/7/2019
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2019.
-
Apyx Medical Corporation Announces Appointment of Minnie Baylor-Henry to the Company’s Board of Directors
8/6/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Minnie Baylor-Henry to the Board of Directors, effective August 1, 2019
-
Apyx Medical Corporation Receives 510(k) Clearance for Next-Generation J-Plasma® Precise Handpiece Designed for Laparoscopic Surgery
8/5/2019
The Company’s J-Plasma handpieces are indicated for cutting, coagulation and ablation of soft tissue during open and laparoscopic surgical procedures.
-
Apyx Medical Corporation Announces New Additions to Clinical and Regulatory Affairs Teams
7/31/2019
Kari Larson Appointed as Senior Director of Clinical Studies; Libet Garber, Ph.D. Appointed as Global Director of Regulatory Affairs
-
Apyx Medical Corporation Announces Appointment of Four Members to its Medical Advisory Board
7/15/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, which is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the appointment of four members to its Medical Advisory Board.
-
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2019 Financial Results on August 7, 2019
7/2/2019
Financial results for the second quarter of fiscal year 2019 will be released after the market closes on Wednesday, August 7.
-
Apyx Medical Corporation Joins Russell 3000® and Russell 2000® Indexes
7/1/2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, announced today that the Company has been added to the Russell 3000® and Russell 2000® Indexes.
-
APYX UPCOMING DEADLINE: Rosen, a Top Ranked Law Firm, Reminds Apyx Medical Corporation Investors of Important Deadline in the Securities Class Action; Encourages Investors with Over $100K in Losses to Contact the Firm - APYX
6/6/2019
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation from August 1, 2018 through April 1, 2019, inclusive of the important June 17, 2019 deadline in the securities class action.
-
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2018 Financial Results on March 13, 2019
2/7/2019
Apyx Medical Corporation announced that financial results for the fourth quarter and fiscal year 2018 will be released after the market closes on Wednesday, March 13.